.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Lower-Risk MDS: A Review of Data from the ASH 2022 Annual Meeting

Experts in hematologic oncology give an overview of first- and second-line MDS treatment options, and discuss updates from the ASH 2022 Annual Meeting.

EP. 1: First- and Second-Line Treatment Options in Lower-Risk MDS

February 24th 2023

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

EP. 2: Luspatercept in Lower-Risk MDS

February 24th 2023

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

EP. 3: Emerging Therapies for Lower-Risk MDS

February 24th 2023

Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.